Stefaan Julien Last

This inventor holds 37 USPTO granted patents and 8 published patent applications, plus 12 CIPO patents and 20 EPO patents, primarily in Viral Infection Treatment. Top assignees: Janssen Sciences Ireland Uc, Janssen Sciences Ireland Unlimited Company, Janssen R&d Ireland. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefaan Julien Last. Retrieved from https://idiyas.com/inventor/stefaan-julien-last

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 8)

% Patents Active = 35.1

CIPO Patents = 12 (Patent Applications = 7)

EPO Patents = 20 (Patent Applications = 27)

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 163(Granted Patents)

Location History:

Beveren, BE (2021 - 2022)
Lint, BE (2010 - 2023)

Company Filing History:

23 out of 111

Janssen Sciences Ireland Uc

patents

6 out of 64

Janssen Sciences Ireland Unlimited Company

Tibotec Pharmaceuticals Ltd.

patents

5. 1 out of 1

Janssen Research & Development Ireland

patent

Years Active: 2010-2023

Loading Chart...

Areas of Expertise:

Pyrimidine Derivatives

Amide Derivatives

Quinazoline Derivatives

Hepatitis B

Viral Infections

HIV Protease Inhibitors

Sulfamoyl Derivatives

Cyclized Sulfamoylarylamides

Phenyl Ethynyl Derivatives

Bis-Benzimidazole Derivatives

Diary Ethers

N-Phenyl-Carboxamide Derivatives

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11541050 - Pyrimidine derivatives for the treatment of viral infections (2023-01-03),

2. 11491148 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2022-11-08),

3. 11220504 - Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases (2022-01-11),

4. 11096931 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2021-08-24),

5. 11078193 - Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B (2021-08-03),

6. 10995064 - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B (2021-05-04),

7. 10941113 - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B (2021-03-09),

8. 10875876 - Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B (2020-12-29),

9. 10781216 - Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases (2020-09-22),

10. 10780089 - Pyrimidine derivatives for the treatment of viral infections (2020-09-22),

11. 10723707 - Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections (2020-07-28),

12. 10676429 - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B (2020-06-09),

13. 10457638 - Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B (2019-10-29),

14. 10420767 - Pyrimidine derivatives for the treatment of viral infections (2019-09-24),

15. 10398677 - N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B (2019-09-03),

Title: Innovations and Contributions of Stefaan Julien Last

Introduction

Stefaan Julien Last, based in Lint, Belgium, is a prominent inventor known for his significant contributions to pharmaceutical innovation. With an impressive portfolio of 37 patents, Last has actively contributed to the field, particularly in developing treatments for viral infections.

Latest Patents

Among his latest inventions, Last has created pyrimidine derivatives aimed at treating viral infections. This invention encompasses the derivatives, processes for their preparation, pharmaceutical compositions, and their application in treating infections like HCV (Hepatitis C Virus) and HBV (Hepatitis B Virus). Another notable patent involves amide derivatives that are particularly useful in treating chronic HBV infection and related diseases. This application highlights the process for synthesizing these derivatives and their therapeutic uses, demonstrating Last's commitment to addressing public health challenges through innovative solutions.

Career Highlights

Stefaan Julien Last has made significant strides in his career while working for esteemed organizations, including Janssen Sciences Ireland UC and Janssen Sciences Ireland Unlimited Company. His work in these companies has allowed him to focus on pharmaceutical research and development, significantly contributing to the advancement of medical treatments.

Collaborations

Throughout his career, Last has collaborated with several talented individuals, including Pierre Jean-Marie Bernard Raboisson and Tim Hugo Maria Jonckers. These collaborations have fostered a dynamic exchange of ideas, enhancing the innovation process and leading to the development of effective pharmaceutical solutions.

Conclusion

In summary, Stefaan Julien Last is an influential figure in the pharmaceutical industry, with a wealth of experience and a robust patent portfolio. His work not only demonstrates the application of scientific research in real-world treatments but also reflects a dedication to improving global health through innovative medical advancements.

Profile summary based on public USPTO records.